Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/28868
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZhuravlyova, Larysa-
dc.contributor.authorPylov, Daniel-
dc.contributor.authorSmirnov, Ivan-
dc.contributor.authorRadzishevska, Yevheniia-
dc.date.accessioned2021-06-12T16:00:15Z-
dc.date.available2021-06-12T16:00:15Z-
dc.date.issued2021-
dc.identifier.citationPrediction of progression of atherosclerosis in patients with type 2 diabetes mellitus and chronic pancreatitis / D. Pylov, L. Zhuravlyova, I. Smirnov, E. Radzishevskaya // EUREKA: Health Sciences. – 2021. – N 1. – P. 24–32.en_US
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/28868-
dc.description.abstractDue to a modern approach to treatment of type 2 diabetes mellitus (DM-2), it is easier to achieve disease compensation nowadays. However, even when blood glucose level is under control, risk of cardiovascular events (CVE) remains in individuals with DM. One of the reasons for occurrence of CVE is the presence of comorbid diseases in DM-2 and a number of other factors, namely: impaired lipid metabolism, inflammatory process, irregular blood glucose level control, which leads to increased time of blood glucose level being beyond the target range. Chronic pancreatitis (CP) is one of the most common comorbid diseases in DM-2.en_US
dc.language.isoenen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.subjectatherosclerosisen_US
dc.subjectcarotid intima media thicknessen_US
dc.subjectvaspinen_US
dc.subjectadipocytokinesen_US
dc.titlePrediction of progression of atherosclerosis in patients with type 2 diabetes mellitus and chronic pancreatitisen_US
dc.typeArticleen_US
Appears in Collections:Наукові праці. Кафедра внутрішньої медицини № 3 та ендокринології

Files in This Item:
File Description SizeFormat 
Article EUREKA Pylov.pdf499,45 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.